KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbCellera Biologics (ABCL) Enterprise Value (2020 - 2026)

AbCellera Biologics filings provide 7 years of Enterprise Value readings, the most recent being -$102.1 million for Q1 2026.

  • Quarterly Enterprise Value rose 83.81% to -$102.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$102.1 million through Mar 2026, up 83.81% year-over-year, with the annual reading at -$558.8 million for FY2025, 14.11% up from the prior year.
  • Enterprise Value hit -$102.1 million in Q1 2026 for AbCellera Biologics, up from -$558.8 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$102.1 million in Q1 2026 and bottomed at -$911.5 million in Q4 2022.
  • Average Enterprise Value over 5 years is -$506.1 million, with a median of -$558.8 million recorded in 2025.
  • The largest annual shift saw Enterprise Value tumbled 310.95% in 2024 before it surged 83.81% in 2026.
  • AbCellera Biologics' Enterprise Value stood at -$911.5 million in 2022, then skyrocketed by 82.63% to -$158.3 million in 2023, then tumbled by 310.95% to -$650.6 million in 2024, then grew by 14.11% to -$558.8 million in 2025, then soared by 81.74% to -$102.1 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Enterprise Value are -$102.1 million (Q1 2026), -$558.8 million (Q4 2025), and -$520.7 million (Q3 2025).